Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

International Journal of Molecular Sciences(2024)10.3390/ijms25042382Source: DataRank Database

ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer is a research paper published in International Journal of Molecular Sciences (2024). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: goldTopics (63)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Yifang Wang ORCID,Xin Sun ORCID,Xiujuan Zhang ORCID,Nicole L. Simone ORCID,Jun He ORCID

Live enrichment

PubMed:38397056 PMC:PMC10888698

National Institutes of Health (NIH)

Grant: R00CA215316

National Institutes of Health (NIH)

Grant: R01CA263506

National Institutes of Health (NIH)

Grant: R01ES027901

NIH HHS

Grant: R00CA215316, R01CA232587, R01CA263506, R01ES027901

National Institutes of Health

Grant: 5R00CA215316-05

New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer

National Institutes of Health

Grant: 5R01ES027901-03

Chromium in carcinogenesis and angiogenesis

National Institutes of Health

Grant: 1R01CA263506-01A1

MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response

goldLicense: cc-by

publisherhttps://www.mdpi.com/1422-0067/25/4/2382/pdf?version=1708407221

publisherhttps://www.mdpi.com/1422-0067/25/4/2382/pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10888698/pdf/ijms-25-02382.pdf

Europe_PMChttps://europepmc.org/articles/PMC10888698

Europe_PMChttps://europepmc.org/articles/PMC10888698?pdf=render

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciencesAnimalsHumansMiceAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationDrug Resistance, NeoplasmErbB Receptorsets-Domain Protein Elk-1GefitinibLung NeoplasmsMice, NudeRibosomal Protein S6 KinasesRNA, Small InterferingSirolimusTOR Serine-Threonine KinasesTyrosine Kinase Inhibitors

MeSH Terms

Cell Line, TumorAnimalsHumansMiceMice, NudeCarcinoma, Non-Small-Cell LungLung NeoplasmsSirolimusRibosomal Protein S6 KinasesRNA, Small InterferingAntineoplastic AgentsCell ProliferationDrug Resistance, Neoplasmets-Domain Protein Elk-1TOR Serine-Threonine KinasesErbB ReceptorsGefitinibTyrosine Kinase Inhibitors

Keywords

ResistanceMtorGefitinibS6k1Egfr-tkiElk1Lung NeoplasmsMice, NudeAntineoplastic AgentsTyrosine Kinase InhibitorsArticleMiceCarcinoma, Non-Small-Cell LungCell Line, TumorAnimalsHumansRNA, Small InterferingCell Proliferationets-Domain Protein Elk-1SirolimusRibosomal Protein S6 KinasesTOR Serine-Threonine KinasesErbB ReceptorsDrug Resistance, Neoplasm

Sustainable Development Goals

SDG 3: 3. Good health